Autolus Therapeutics Stock Price Prediction
| AUTL Stock | USD 2.94 0.10 3.52% |
Oversold Vs Overbought
45
Oversold | Overbought |
EPS Estimate Next Quarter (0.20) | EPS Estimate Current Year (0.91) | EPS Estimate Next Year (0.80) | Wall Street Target Price 10.45 | EPS Estimate Current Quarter (0.21) |
Using Autolus Therapeutics hype-based prediction, you can estimate the value of Autolus Therapeutics from the perspective of Autolus Therapeutics response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Autolus Therapeutics to buy its stock at a price that has no basis in reality. In that case, they are not buying Autolus because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Autolus Therapeutics after-hype prediction price | USD 2.84 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Autolus |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Autolus Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Autolus Therapeutics After-Hype Price Prediction Density Analysis
As far as predicting the price of Autolus Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Autolus Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Autolus Therapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Autolus Therapeutics Estimiated After-Hype Price Volatility
In the context of predicting Autolus Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Autolus Therapeutics' historical news coverage. Autolus Therapeutics' after-hype downside and upside margins for the prediction period are 0.14 and 7.55, respectively. We have considered Autolus Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Autolus Therapeutics is very risky at this time. Analysis and calculation of next after-hype price of Autolus Therapeutics is based on 3 months time horizon.
Autolus Therapeutics Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Autolus Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Autolus Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Autolus Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.36 | 4.74 | 0.07 | 0.09 | 9 Events / Month | 13 Events / Month | In about 9 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
2.94 | 2.84 | 0.00 |
|
Autolus Therapeutics Hype Timeline
Autolus Therapeutics is presently traded for 2.94. The entity has historical hype elasticity of 0.07, and average elasticity to hype of competition of 0.09. Autolus is anticipated not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is over 100%. The immediate return on the next news is anticipated to be very small, whereas the daily expected return is presently at -0.36%. %. The volatility of related hype on Autolus Therapeutics is about 1975.0%, with the expected price after the next announcement by competition of 3.03. About 18.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.56. Some equities with similar Price to Book (P/B) outperform the market in the long run. Autolus Therapeutics recorded a loss per share of 1.22. The entity had not issued any dividends in recent years. Given the investment horizon of 90 days the next anticipated press release will be in about 9 days. Check out Autolus Therapeutics Basic Forecasting Models to cross-verify your projections.Autolus Therapeutics Related Hype Analysis
Having access to credible news sources related to Autolus Therapeutics' direct competition is more important than ever and may enhance your ability to predict Autolus Therapeutics' future price movements. Getting to know how Autolus Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Autolus Therapeutics may potentially react to the hype associated with one of its peers.
Autolus Therapeutics Additional Predictive Modules
Most predictive techniques to examine Autolus price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Autolus using various technical indicators. When you analyze Autolus charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Autolus Therapeutics Predictive Indicators
The successful prediction of Autolus Therapeutics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Autolus Therapeutics, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Autolus Therapeutics based on analysis of Autolus Therapeutics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Autolus Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Autolus Therapeutics's related companies. | 2021 | 2022 | 2023 | 2024 (projected) | Days Sales Outstanding | 10.65 | 9.02 | 5.3K | 5.9K | PTB Ratio | 1.19 | 0.6 | 10.05 | 6.27 |
Story Coverage note for Autolus Therapeutics
The number of cover stories for Autolus Therapeutics depends on current market conditions and Autolus Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Autolus Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Autolus Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Other Macroaxis Stories
Our audience includes start-ups and big corporations as well as marketing, public relation firms, and advertising agencies, including technology and finance journalists. Our platform and its news and story outlet are popular among finance students, amateur traders, self-guided investors, entrepreneurs, retirees and baby boomers, academic researchers, financial advisers, as well as professional money managers - a very diverse and influential demographic landscape united by one goal - build optimal investment portfolios
Story Categories
Currently Trending Categories
Autolus Therapeutics Short Properties
Autolus Therapeutics' future price predictability will typically decrease when Autolus Therapeutics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Autolus Therapeutics often depends not only on the future outlook of the potential Autolus Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Autolus Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 173.9 M | |
| Cash And Short Term Investments | 239.6 M |
Check out Autolus Therapeutics Basic Forecasting Models to cross-verify your projections. For more information on how to buy Autolus Stock please use our How to buy in Autolus Stock guide.You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Autolus Therapeutics. If investors know Autolus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Autolus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.22) | Revenue Per Share 0.043 | Quarterly Revenue Growth 6.81 | Return On Assets (0.22) | Return On Equity (0.82) |
The market value of Autolus Therapeutics is measured differently than its book value, which is the value of Autolus that is recorded on the company's balance sheet. Investors also form their own opinion of Autolus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Autolus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Autolus Therapeutics' market value can be influenced by many factors that don't directly affect Autolus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Autolus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Autolus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Autolus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.